RJFSA
ALXN

Raymond James Financial Services Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-36,900
Closed -$6K – 2411
2016
Q2 		$6K Sell
36,900
-200
-0.5% -$28.4K ﹤0.01% 2272
2016
Q1 		$39K Buy
+37,100
New +$5.45M ﹤0.01% 1983

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Raymond James Financial Services Advisors's ALXN Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 35,079 shares — an estimated $6.44M sold.

Raymond James Financial Services Advisors first reported a position in ALXN in Q4 2015 and held it in 23 quarters. The position peaked at $22.3M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 35,079 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.44M.
  • Raymond James Financial Services Advisors first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 23 quarters.
  • Raymond James Financial Services Advisors's Alexion Pharmaceuticals position peaked at $22.3M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.